Market Overview

UPDATE: Jefferies Upgrades Sabra Health Care REIT on Attractive Entry Point

Related SBRA
UPDATE: Bank Of America Upgrades Sabra Health Care REIT On Valuation
MLV & Co Sees Attractive Value From Sabra Health Care REIT

In a report published Wednesday, Jefferies analyst Omotayo Okusanya upgraded the rating on Sabra Health Care REIT (NASDAQ: SBRA) from Hold to Buy, but lowered the price target from $27.00 to $26.00.

In the report, Jefferies noted, “We had previously downgraded SBRA stock from Buy to Hold back in April on concerns of valuation following a 250% run-up in the stock since 2011. However, with the stock now down over 26% since May, shares appear oversold, offering an attractive entry point. While a rising cost of capital and recent lack of deal flow are concerns, recent pipeline agreements suggest new transactions are imminent. Upgrade to Buy but lower PT to $26.”

Sabra Health Care REIT closed on Tuesday at $22.49.

Latest Ratings for SBRA

DateFirmActionFromTo
Oct 2014BarclaysUpgradesEqual-weightOverweight
Oct 2014Bank of AmericaUpgradesNeutralBuy
Aug 2014JefferiesMaintainsBuy

View More Analyst Ratings for SBRA
View the Latest Analyst Ratings

Posted-In: Jefferies Omotayo OkusanyaAnalyst Color Upgrades Analyst Ratings

 

Related Articles (SBRA)

Around the Web, We're Loving...

Get Benzinga's Newsletters